Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ERN1 | O75460 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7555323 | 0.89 | TSHR (0.50) | GPR35CYP3A4MAPTALDH1A1KDM4E | |
| SCHEMBL10013940 | 0.81 | GPR35 (0.69) | GPR35MAPTERN1LMNA | |
| SCHEMBL7101305 | 0.81 | ERN1 (0.65) | GPR35CYP3A4MAPTALDH1A1KDM4E | |
| SCHEMBL15776986 | 0.81 | MAPT (0.47) | CYP3A4MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL15776593 | 0.81 | CYP3A4 (0.45) | GPR35CYP3A4MAPTALDH1A1KDM4E | |
| SCHEMBL260768 | 0.81 | GPR35 (0.67) | GPR35CYP3A4MAPTALDH1A1KDM4E | |
| SCHEMBL13883997 | 0.78 | GPR35 (0.57) | GPR35CYP3A4MAPTALDH1A1KDM4E | |
| SCHEMBL19785896 | 0.78 | CYP3A4 (0.41) | CYP3A4MAPTALDH1A1KDM4EALOX15 | |
| Benzene SCHEMBL27490159 | 0.77 | GPR35 (0.61) | GPR35CYP3A4MAPTALDH1A1KDM4E | |
| SCHEMBL3017185 | 0.77 | TSHR (0.62) | GPR35CYP3A4MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476653-B | Heteroaromatic modulators of retinoid-related orphan receptor gamma | 利奥制药有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S | 2020-09-17 | — | — | US | disclosed |
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S | 2020-09-17 | — | — | US | disclosed |
| EP-3484880-B1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA AS (DK) | 2020-09-02 | — | — | EP | disclosed |
| EP-3484880-B1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA AS (DK) | 2020-09-02 | — | — | EP | disclosed |
| EP-2906216-B1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-10662181-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2020-05-26 | — | — | US | disclosed |
| US-10662181-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2020-05-26 | — | — | US | disclosed |
| US-9643979-B2 | Inhibitors of DNA gyrase for the treatment of bacterial infections | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR, AJAY, DR. (GB) | 2015-10-08 | — | — | US | disclosed |
| WO-2015131200-A1 | SMALL MOLECULE XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | BAYLOR COLLEGE OF MEDICINE (US) | 2015-09-03 | — | — | WO | disclosed |
| EP-2906216-A2 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | Vitas Pharma Research Private Limited (IN) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014057415-A2 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PVT LTD (IN) | 2014-04-17 | — | — | WO | disclosed |
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| EP-1259491-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | Abbott Laboratories (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060802-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-08-23 | — | — | WO | disclosed |
| US-4444776-A | ANTITUMOR, ANTIVIRAL | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (A N V A R) (FR) | 1984-04-24 | — | — | US | disclosed |
| US-4266060-A | ANTITUMOR ANTIVIRAL AGENTS FOR TREATMENT OF CANCER | AGENCE NATIONALE DE VAL ORISATION DE LA RECHERCHE (ANVAR) (FR) | 1981-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | GPR35 612/4885CYP3A4 720/4885MAPT 4075/4885 |
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RXRA, RORA, NR1H3 | GPR35 180/4885CYP3A4 396/4885MAPT 4660/4885 |
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | TOP1, TOP2A, DNASE1 | GPR35 4260/4885CYP3A4 1533/4885MAPT 3965/4885 |
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | RXRA, RXRG, RXRB | GPR35 154/4885CYP3A4 313/4885MAPT 4779/4885 |
| US-10662181-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | RXRA, RXRG, RXRB | GPR35 154/4885CYP3A4 313/4885MAPT 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.